Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Other Events
Item 8.01. Other Events.
On March7, 2017, Novelion Therapeutics Inc. issued a press
release announcing that the Patent Trial and Appeal Board of the
U.S. Patent and Trademark Office issued its final decision in the
inter partes review proceeding initiated by the Coalition for
Affordable Drugs VIII, LLC against U.S. Patent Nos. 7,932,268 and
8,618,135 concerning the dosage regimen of JUXTAPID, affirming
the patentability of all claims under such patents. The press
release is attached as Exhibit99.1 to this Current Report on
Form8-K and is incorporated by reference into this Item 8.01.
Item 9.01. Financial Statements and
Exhibits.
(d)Exhibits.
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release, dated March7, 2017. |
About Novelion Therapeutics Inc. (NASDAQ:NVLN)
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. Novelion Therapeutics Inc. (NASDAQ:NVLN) Recent Trading Information
Novelion Therapeutics Inc. (NASDAQ:NVLN) closed its last trading session 00.00 at 10.78 with 617,244 shares trading hands.
